Ann: Comment on research report, page-114

I have learnt the hard way that where there is smoke, there may be fire. However in this case, it seems to me that there is only shorter BS. I'm heartened by the following:

Reading " The Gillette Children's Difference in Rett Syndrome and Rare Disease Care | Gillette Children's (gillettechildrens.org) "
dated USA time February 15, 2024, gives me confidence that all is ok with Daybue, as per extracts below:

"There’s renewed hope for patients diagnosed with Rett syndrome a year after the FDA approved Daybue (trofinetide) as the first approved treatment to help people diagnosed with the rare neurodevelopmental disorder."

"About 50 Gillette Children’s patients diagnosed with Rett syndrome have been taking Daybue (trofinetide) for about a year."

“These patients are improving incrementally, and we see improvements in communication skills, breathing and overall quality of life,” says Arthur Beisang, MD, co-director of the Gillette Children’s Rett Syndrome Center of Excellence. "

"Dr. Beisang and Dr. Feyma are pleased there is now hope and treatment options for Rett syndrome patients, but both say this progress is the result of many years of hard work and the dedication of parents. They also stress Daybue is a treatment for Rett and not a cure."